Detection of novel germline mutations for breast cancer in non-BRCA1/2 families

FEBS Journal

Volumn 282, Issue 17, 2015, Pages 3424-3437

  Aloraifi, Fatima ^a   McDevitt, Trudi ^b   Martiniano, Rui ^a   McGreevy, Jonah ^a   McLaughlin, Russell ^a   Egan, Chris M ^a   Cody, Nuala ^b   Meany, Marie ^b   Kenny, Elaine ^a   Green, Andrew J ^b   Bradley, Daniel G ^a   Geraghty, James G ^c   Bracken, Adrian P ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

BRCA1; BRCA2; familial breast cancer; genetics; next generation sequencing

Indexed keywords

ATM PROTEIN; CASPASE 8; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; RAD50 PROTEIN; ANRIL LONG NON-CODING RNA, HUMAN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; LONG UNTRANSLATED RNA; MAP3K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; RAD51B PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ARTICLE; ATM GENE; BREAST CANCER; BREAST CARCINOGENESIS; CASP8 GENE; CDKN2B AS1 GENE; CHEK2 GENE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERBB2 GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAP3K1 GENE; MOLECULAR PATHOLOGY; MRE11A GENE; NEXT GENERATION SEQUENCING; ONCOGENE; PALB2 GENE; PREDICTION; PRIORITY JOURNAL; RAD50 GENE; RAD51B GENE; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; ZNF217 GENE; ADULT; BREAST NEOPLASMS; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASPASE 8; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; MAP KINASE KINASE KINASE 1; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RNA, LONG NONCODING; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS;

EID: 84940705329     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13352     Document Type: Article

References (69)

1. Meijers-Heijboer H, van Geel B, van Putten W, Henzen-Logmans S, Seynaeve C, Menke-Pluymers M, Bartels C, Verhoog L, van den Ouweland A, Niermeijer M, et al,. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345, 159-164.
2. Hartmann L, Schaid D, Woods J, Crotty T, Myers J, Arnold P, Petty P, Sellers T, Johnson J, McDonnell S, et al,. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340, 77-84.
3. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, &, Plewes D, (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148, 671-679.
4. Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T, Santarosa M, Dillon K, Hickson I, Knights C, et al,. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
5. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et al,. (2006) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39, 165-167.
6. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, et al,. (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38, 873-875.
7. Lalloo F, &, Evans D, (2012) Familial breast cancer. Clin Genet 82, 105-114.
8. Eccles S, Aboagye E, Ali S, Anderson A, Armes J, Berditchevski F, Blaydes J, Brennan K, Brown N, Bryant H, et al,. (2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 15, R92.
9. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne R, Schmidt M, Chang-Claude J, Bojesen S, Bolla M, et al,. (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45, 353-361.
10. Sakoda L, Jorgenson E, &, Witte J, (2013) Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 45, 345-348.
11. Peng S, Lü B, Ruan W, Zhu Y, Sheng H, &, Lai M, (2011) Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 127, 309-324.
12. Zhang B, Beeghly-Fadiel A, Long J, &, Zheng W, (2011) Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 12, 477-488.
13. Manolio T, Collins F, Cox N, Goldstein D, Hindorff L, Hunter D, McCarthy M, Ramos E, Cardon L, Chakravarti A, et al,. (2009) Finding the missing heritability of complex diseases. Nature 461, 747-753.
14. Huusko P, Juo S, Gillanders E, Sarantaus L, Kainu T, Vahteristo P, Allinen M, Jones M, Rapakko K, Eerola H, et al,. (2003) Genome-wide scanning for linkage in Finnish breast cancer families. Eur J Hum Genet 12, 98-104.
15. Smith P, McGuffog L, Easton D, Mann G, Pupo G, Newman B, Chenevix-Trench G, Szabo C, Southey M, Renard H, et al,. (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom Cancer 45, 646-655.
16. O'Dushlaine C, Morris D, Moskvina V, Kirov G, Consortium I, Gill M, Corvin A, Wilson J, &, Cavalleri G, (2010) Population structure and genome-wide patterns of variation in Ireland and Britain. Eur J Hum Genet 18, 1248-1254.
17. Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al,. (2010) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39, D945-D950.
18. Snape K, Ruark E, Tarpey P, Renwick A, Turnbull C, Seal S, Murray A, Hanks S, Douglas J, Stratton M, et al,. (2012) Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer. Breast Cancer Res Treat 134, 429-433.
19. Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm J, Dobson J, Urashima M, et al,. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905.
20. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, &, Van Criekinge W, (2007) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36, D842-D846.
21. Dawson M, &, Kouzarides T, (2012) Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
22. Rehm H, (2013) Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet 14, 295-300.
23. Marchini J, Cardon LR, Phillips MS, &, Donnelly P, (2004) The effects of human population structure on large genetic association studies. Nat Genet 36, 512.
24. Mathieson I, &, McVean G, (2012) Differential confounding of rare and common variants in spatially structured populations. Nat Genet 44, 243.
25. Do R, Kathiresan S, &, Abecasis G, (2012) Exome sequencing and complex disease: practical aspects of rare variant association studies. Hum Mol Genet 21, R1-R9.
26. De Baets G, Van Durme J, Reumers J, Maurer-Stroh S, Vanhee P, Dopazo J, Schymkowitz J, &, Rousseau F, (2011) SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants. Nucleic Acids Res 40, D935-D939.
27. Cingolani P, Patel V, Coon M, Nguyen T, Land S, Ruden D, &, Lu X, (2012) Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet 3, 35.
28. Liu X, Jian X, &, Boerwinkle E, (2013) dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat 34, E2393-E2402.
29. Reva B, Antipin Y, &, Sander C, (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39, e118.
30. Sim N, Kumar P, Hu J, Henikoff S, Schneider G, &, Ng P, (2012) SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40, W452-W457.
31. Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P, Kondrashov A, &, Sunyaev S, (2010) A method and server for predicting damaging missense mutations. Nat Methods 7, 248-249.
32. Schwarz J, Rödelsperger C, Schuelke M, &, Seelow D, (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7, 575-576.
33. MacArthur D, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, Jostins L, Habegger L, Pickrell J, Montgomery S, et al,. (2012) A systematic survey of loss-of-function variants in human protein-coding genes. Science 335, 823-828.
34. Hollestelle A, Wasielewski M, Martens J, &, Schutte M, (2010) Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 20, 268-276.
35. Apweiler R, (2001) The InterPro database, an integrated documentation resource for protein families, domains and functional sites. Nucleic Acids Res 29, 37-40.
36. Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P, Yaswen P, &, Sweeney C, (2010) ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 29, 5500-5510.
37. Kurian A, Gong G, John E, Johnston D, Felberg A, West D, Miron A, Andrulis I, Hopper J, Knight J, et al,. (2011) Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the breast cancer family registry. J Clin Oncol 29, 4505-4509.
38. Rivas M, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang C, Boucher G, Ripke S, Ellinghaus D, Burtt N, et al,. (2011) Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 43, 1066-1073.
39. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma V, et al,. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1∗2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40, 844-853.
40. Bargmann CI, Hung MC, &, Weinberg R, (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
41. Schechter A, Stern D, &, Vaidyanathan L, (1984) The neu oncogene: an erb-B- related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513-516.
42. Fan YX, Won L, Ding J, Spiridonov NA, Johnson RC, &, Johnson GR, (2008) Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem 283, 1588-1596.
43. Baxter SW, &, Campbell IG, (2001) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93, 557-559.
44. Hauptmann M, Sigurdson AJ, Chatterjee N, Rutter JL, Hill DA, Doody MM, &, Struewing JP, (2003) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 95, 1251-1252.
45. Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, Emi N, &, Tajima K, (2002) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94, 1807-1808.
46. Keshava C, McCanlies EC, Keshava N, Wolff MS, &, Weston A, (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173, 37-41.
47. Mckean-cowdin R, Kolonel LN, Press MF, Pike MC, &, Henderson BE, (2001) Germ-line HER-2 variant and breast cancer risk by stage of disease germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61, 8393-8394.
48. Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, &, Campbell IG, (2003) The HER2 I655V polymorphism and risk of breast cancer in women< age 40 years. Cancer Epidemiol Biomark Prev 12, 1109-1111.
49. Wang-Gohrke S, &, Chang-Claude J, (2001) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93, 1657-1659.
50. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, &, Zheng W, (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92, 412-417.
51. Dahabreh IJ, &, Murray S, (2011) Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 35, 503-509.
52. Gracia-Aznarez F, Fernandez V, Pita G, Peterlongo P, Dominguez O, de la Hoya M, Duran M, Osorio A, Moreno L, Gonzalez-Neira A, et al,. (2013) Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 8, e55681.
53. Hilbers F, Meijers C, Laros J, van Galen M, Hoogerbrugge N, Vasen H, Nederlof P, Wijnen J, van Asperen C, &, Devilee P, (2013) Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling. PLoS One 8, e55734.
54. Park D, Odefrey F, Hammet F, Giles G, &, Baglietto L, ABCFS, MCCS, Hopper J, Schmidt D, Makalic E, Sinilnikova O, Goldgar D, &, Southey M, (2011) FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer. Breast Cancer Res Treat 130, 1043-1049.
55. Thompson E, Doyle M, Ryland G, Rowley S, Choong D, Tothill R, Thorne H, Barnes D, Li J, Ellul J, et al,. (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 8, e1002894.
56. Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A, Carter S, Stewart C, Mermel C, Roberts S, et al,. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218.
57. Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D, Zainal S, Martin S, Varela I, Bignell G, et al,. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404.
58. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
59. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, &, Cooper DN, (2003) Human gene mutation database. Hum Mutat 21, 577-581.
60. Laird NM, &, Lange C, (2006) Family-based designs in the age of large-scale gene-association studies. Nat Rev Genet 7, 385-394.
61. Little J, Bradley L, Bray M, Clyne M, Dorman J, Ellsworth D, Hanson J, Khoury M, Lau J, O'Brien T, et al,. (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156, 300-310.
62. DePinho RA, (2000) The age of cancer. Nature 408, 248-254.
63. Li H, &, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
64. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, &, Durbin R, (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079.
65. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al,. (2010) The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297-1303.
66. DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C, Philippakis A, del Angel G, Rivas M, Hanna M, et al,. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43, 491-498.
67. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D, Maller J, Sklar P, de Bakker P, Daly M, et al,. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575.
68. Patterson N, Price A, &, Reich D, (2006) Population structure and eigenanalysis. PLoS Genet 2, e190.
69. Kumar P, Henikoff S, &, Ng PC, (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4, 1073-1081.